Medical School:

• Harvard Medical School, 2006

Residency (Urology):

• Massachusetts General Hospital, 2012

Fellowship (Urologic Oncology):

• National Institutes of Health Clinical Center - Urologic Oncology, 2014

Certification:

• American Board of Urology - Urology, 2016

Dr. Mohummad Siddiqui is a fellowship-trained specialist in Urologic Oncology and Robotic Surgery.  He joined the faculty at the University of Maryland in 2014 after completing training at MIT, Harvard, and the NIH in the field of Urology and subspecialty of Urologic Oncology.  He is the Director of Urologic Oncology and Robotic Surgery at the University of Maryland Medical Center.  He specializes in the surgical management of urologic cancers such as prostate, bladder, kidney, and testicular cancer.  

Dr. Siddiqui is dedicated to providing the highest quality, cutting-edge care to his patients while minimizing the impact that treatment has on their quality of life.  He utilizes the DaVinci robot when appropriate for his surgical procedures, but he also values the opinion that in cases when a disease can be managed without surgery (such as with active surveillance) or with minimal  intervention such as with prostate focal therapy with MRI guidance, these options may be the best treatment path for the patient.  We are actively developing a program in focal therapy of the prostate investigating approaches such as focal brachytherapy, IRE (irreversable electroporation) and cryotherapy.

We also have established a team to study alternate lifestyle changes, such as changes in diet, to better manage prostate cancer.  We have an ongoing trial in coordination with a multidisciplinary team including a dietician to implement diet changes, such as the ketogenic diet, in men diagnosed with prostate cancer.  We have a lab in which we study the changes in cancer metabolism as cancers go from less aggressive to more aggressive types.

Dr. Siddiqui has established a medical practice specialized in patients with complex presentations such as patients with extensive medical histories and patients with aggressive, complex tumors.  He furthermore maintains active research programs testing the use of diet to improve cancer outcomes and the use of imaging to better identify, and ultimately treat urologic cancers

Videos:  More information about prostate cancer can be viewed in the following videos:

• Prostate Cancer Screening and Early Detection
• Prostate Cancer Overview: PATIENTS program

Information about MRI guided prostate biopsy can be seen at:

• MRI guided Fusion MR/Ulrasound prostate biopsy

Prostate cancer, Bladder cancer, Testicular cancer, Kidney cancer, Adrenal cancer, Robotic Surgery, Prostate focal therapy, Diet and cancer, Urologic oncology, Minimally invasive urologic surgery, MRI Fusion guided prostate biopsy, Magnetic resonance imaging,

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. Siddiqui MM Rais-Bahrami S Turkbey B George AK Rothwax J Shakir N Okoro C Raskolnikov D Parnes HL Linehan WM Merino MJ Simon RM Choyke PL Wood BJ Pinto PA JAMA 2015 Jan 27

Urothelial Carcinoma. So C, Siddiqui MM The New England journal of medicine

Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-Up Study. Siddiqui MM Wilson KM Epstein MM Rider JR Martin NE Stampfer MJ Giovannucci EL Mucci LA J Clin Oncol 2014 Jul

Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. Siddiqui MM, George AK, Rubin R, Rais-Bahrami S, Parnes HL, Merino MJ, Simon RM, Turkbey B, Choyke PL, Wood BJ, Pinto PA J Natl Cancer Inst 2016 Sep The Metabolic Phenotype of Prostate Cancer. Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM Frontiers in oncology 2017-06

Evaluation of Cancer-Specific Mortality with Surgery Versus Radiation as Primary Therapy for Localized High-Grade Prostate Cancer in Men Younger than 60 Years Old. Huang H, Muscatelli S, Naslund M, Badiyan SN, Kaiser A, Siddiqui MM The Journal of urology 2018-07-2

A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. Mehralivand S, Shih JH, Rais-Bahrami S, Oto A, Bednarova S, Nix JW, Thomas JV, Gordetsky JB, Gaur S, Harmon SA, Siddiqui MM, Merino MJ, Parnes HL, Wood BJ, Pinto PA, Choyke PL, Turkbey B JAMA oncolog

Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men. Kongnyuy M, Siddiqui MM, George AK, Muthigi A, Sidana A, Maruf M, Turkbey B, Choyke PL, Wood BJ, Pinto PA Prostate cancer and prostatic diseases 2017-04-25

Contact: